Sahay Sandeep, Rahaghi Franck
Houston Methodist Hospital, Houston, USA.
Pulm Circ. 2020 Feb 28;10(1):2045894020910098. doi: 10.1177/2045894020910098. eCollection 2020 Jan-Mar.
Pulmonary arterial hypertension is a progressive disease that can lead to right-sided ventricular failure and premature death. Tailoring therapy to individual patient's needs, along with regular risk assessment, is integral for optimal outcomes in patients with pulmonary arterial hypertension. Results from the AMBITION trial support the use of upfront combination of tadalafil and ambrisentan. In a recent analysis of risk assessment in pulmonary arterial hypertension, abridged versions of the REVEAL 2.0 risk score were shown to be comparable to the full tools. In this report, we present a case series of the use of riociguat in upfront combination or sequentially, and the impact on risk scores as determined by the abridged REVEAL Lite 2.0 approach.
肺动脉高压是一种进行性疾病，可导致右心室衰竭和过早死亡。根据个体患者的需求调整治疗方案，并定期进行风险评估，对于肺动脉高压患者获得最佳治疗效果至关重要。AMBITION试验的结果支持早期联合使用他达拉非和安立生坦。在最近一项关于肺动脉高压风险评估的分析中，REVEAL 2.0风险评分的简化版本被证明与完整工具相当。在本报告中，我们展示了一组关于利奥西呱早期联合使用或序贯使用的病例系列，以及采用简化的REVEAL Lite 2.0方法确定的其对风险评分的影响。
